Abstract:PurposeAccurate staging of ovarian cancer is critical to guide optimal management pathways. North American guidelines recommend contrast-enhanced CT as the primary work-up for staging ovarian cancer. This meta-analysis aims to compare the diagnostic accuracy of contrast-enhanced CT alone to PET/CT for detecting abdominal metastases in patients with a new or suspected diagnosis of ovarian cancer.Materials and methodsA systematic review of MEDLINE, EMBASE, Scopus, the Cochrane Library, and the gray literature from inception to October 2022 was performed. Studies with a minimum of 5 patients evaluating the diagnostic accuracy of contrast-enhanced CT and/or PET/CT for detecting stage 3 ovarian cancer as defined by a surgical/histopathological reference standard ± clinical follow-up were included. Study, clinical, imaging, and accuracy data for eligible studies were independently acquired by two reviewers. Primary meta-analysis was performed in studies reporting accuracy on a per-patient basis using a bivariate mixed-effects regression model. Risk of bias was evaluated using QUADAS-2.ResultsFrom 3701 citations, 15 studies (918 patients with mean age ranging from 51 to 65 years) were included in the systematic review. Twelve studies evaluated contrast-enhanced CT (6 using a per-patient assessment and 6 using a per-region assessment) and 11 studies evaluated PET/CT (7 using a per-patient assessment and 4 using a per-region assessment). All but one reporting study used consensus reading. Respective sensitivity and specificity values on a per-patient basis were 82% (67–91%, 95% CI) and 72% (59–82%) for contrast-enhanced CT and 87% (75–94%) and 90% (82–95%) for PET/CT. There was no significant difference in sensitivities between modalities (p = 0.29), but PET/CT was significantly more specific than CT (p < 0.01). Presumed variability could not be assessed in any single category due to limited studies using per-patient assessment. Studies were almost entirely low risk for bias and applicability concerns using QUADAS-2.ConclusionContrast-enhanced CT demonstrates non-inferior sensitivity compared to PET/CT, although PET/CT may still serve as an alternative and/or supplement to CT alone prior to and/or in lieu of diagnostic laparoscopy in patients with ovarian cancer. Future revisions to existing guidelines should consider these results to further refine the individualized pretherapeutic diagnostic pathway.

Imaging ovarian cancer and peritoneal metastases—current and emerging techniques

Imaging techniques for the evaluation of ovarian cancer

Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques

Update on Imaging of Ovarian Cancer

Ovarian Cancer Management: The role of imaging and diagnostic challenges

Imaging of peritoneal deposits in ovarian cancer: A pictorial review

Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives

Novel imaging techniques in gynaecological cancer

Recent Imaging Updates and Advances in Gynecologic Malignancies

Imaging of Peritoneal Metastases in Ovarian Cancer Using MDCT, MRI, and FDG PET/CT: A Systematic Review and Meta-Analysis

Imaging of peritoneal metastases of ovarian and colorectal cancer: joint recommendations of ESGAR, ESUR, PSOGI, and EANM

Imaging strategy in recurrent ovarian cancer: a practical review

Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review

Role of MRI in Pre-Operative Assessment of Patients with Advanced Ovarian Cancer Candidate for Cytoreductive Surgery, A Brief Review

Imaging in malignant peritoneal neoplasms

Ovarian Cancer: Detection and Radiologic Staging

Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment

A Systematic Review of Imaging Assessment

Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer

Diagnostic accuracy of contrast-enhanced CT versus PET/CT for advanced ovarian cancer staging: a comparative systematic review and meta-analysis

Imaging of colon and rectal cancer